The in vitro cytotoxicity and in vivo efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) can be markedly enhanced in combination with certain radiation sensitizing compounds (reviewed by Siemann, 1982) , most notably Misonidazole (MISO). CCNU, like other nitrosoureas, undergoes a spontaneous chemical decomposition to yield two active species, an alkylating chloroethyl carbonium ion as well as a carbamoylating isocyanate (Montgomery et al., 1967) . Alkylation is considered to be responsible for cytotoxicity (Wheeler et al., 1974) , while carbamoylation can account for the inhibition of protein-mediated processes such as the repair of DNA damage (Kann et al., 1980) and the regeneration of intracellular glutatione (Babson & Reed, 1978) . When administered in vivo certain nitrosoureas, including CCNU, are modified by hepatic mixed-function oxidases prior to their decomposition to therapeutically active species. In the case of CCNU, the cyclohexyl ring of the parent drug is rapidly hydroxylated at multiple sites to yield a mixture of cis-and trans-hydroxylated analogs, some of which have properties significantly different from those of the parent compound (May et al., 1974; Hilton & Walter, 1975; Wheeler et al., 1977 between fully aerobic and radiobiologically hypoxic, the magnitude of enhancement is greatest under hypoxic conditions (Mulcahy, 1984) . Therefore, for these experiments EMT-6/Ro cells were treated with each of the nitrosoureas alone or in combination with 1.0mM MISO under hypoxic conditions (< 10 ppm 02). Details of the experimental methodology are described in detail elsewhere (Mulcahy et al., 1984) . Briefly, for each treatment group 10.0ml of complete BME medium was gassed for 3 h with a 97% N2/3% CO2 gas mixture while being stirred. At the conclusion of the gassing phase cells were injected onto each of the treatment vials. Prior to injection the cells were incubated for 10min at a concentration of -2x 107ml -1 in a Hamilton air-tight syringe at 37°C to reduce oxygen by consumption. In separate experiments it was determined that this treatment did not influence the response of EMT-6/Ro cells to subsequent nitrosourea treatment.
To initiate exposure, various concentrations of the nitrosoureas were injected into each of the treatment vials, without interrupting gassing. The nitrosoureas were initially dissolved in absolute ethanol and were diluted 1:100 upon addition to the treatment vials. The final concentration of alcohol (1%) did not significantly influence the plating efficiency relative to controls. For those experiments in which cells were exposed to MISO and the nitrosoureas simultaneously, MISO was dissolved in complete BME at a concentration of 1.0 mM prior to the initiation of the gassing sequence. During the entire exposure period the vials were continuously purged with the gas mixture. Four hours after injection of the drugs the medium containing drugs and cells was removed from each vial. The cells were centrifuged, washed and resuspended in fresh BME. Survival was determined using a standard plating efficiency assay. Survival curves were generated by fitting the data to a linear quadratic model by least squares analysis. Dose Enhancement Factors (DEF; defined as the ratio of nitrosourea doses required to reduce cell survival to 0.001 alone or in combination with MISO) were determined from the resultant dose response curves according to the following equation:
© The cytotoxicity of the trans-2-OH or trans-4-OH analogue was not significantly different from that for CCNU (analysis of covaraince; P > 0.1). However, cis-4-OH CCNU was significantly more toxic than CCNU, while the cis-2-OH isomer was significantly less effective (analysis of covariance; P < 0.05). Cytotoxicity of all four isomers was significantly (P<0.01) enhanced in combination with 1.0mM MISO (Figure 1 ). DEFs (95% conf. int.) of 1.3 (1.2-1.4), 2.0 (1.8-2.2), 1.8 (1.7-1.9) and 1.7 (1.6-1.9) were produced when MISO was combined with cis-4-OH, trans-2-OH, cis-2-OH and trans-4-OH CCNU, respectively. The enhancements for the latter three drugs are comparable to those observed when MISO is combined with the parent CCNU in vitro (DEF= 1.6-1.8; Mulcahy et al., 1984) .
These studies indicate that MISO is capable of enhancing the cytotoxicity of monohydroxy-CCNU metabolites, as well as CCNU in vitro. Since in previous studies compounds enhanced by MISO in vitro have been similarly enhanced in vivo (Mulcahy, 1982; Mulcahy et al., 1984) , it seems likely that the effectiveness of the monohydroxylated analogues of CCNU, the major metabolites and immediate precursors of alkylating and carbamoylating moieties, will be potentiated in combination with MISO in vivo. This may be important in relation to the observations by Lee & Workman (1983) that the concentrations of the major CCNU metabolites are elevated following administration of large single doses of MISO. They maintain that the pharmacokinetic alterations observed subsequent to MISO administration are a major factor in the chemopotentiation of CCNU. While the increase in the concentration of these cytotoxic moieties undoubtedly contributes to the enhancement of CCNU cytotoxicity by large doses of MISO in vivo, our investigations suggest that MISO is capable of interacting with the major metabolites of CCNU in a non-pharmacokinetic fashion to enhance their cytotoxicity. We contend that this interaction may actually predominate when lower doses of MISO are employed. Since the enhancements produced when MISO is combined with hydroxylated metabolites of CCNU are, in general, comparable to those observed for CCNU itself, MISO-induced alterations in the rate of CCNU conversion or in the distribution of major monohydroxylated products are unlikely to adversely effect the enhancement of toxicity in vivo.
